dr reddys laboratories

USFDA issues Establishment Inspection Report for Dr Reddy's Bollaram plant

The receipt of EIR indicated closure of the audit of the Bollaram facility

60% of Nifty and 70% of Nifty500 stocks record ‘Death Cross’ on daily charts; a major selloff imminent?

The Nifty might have turned negative for 2019, but almost 60% of index constituents are in a bear grip as registered by the 'Death Cross' formation

Dr Reddy's launches heartburn capsules in US market

The company has launched Lansoprazole delayed-release capsules USP in the strength of 15 mg in the US market, as approved by the United States Food and Drug Administration (USFDA), Dr Reddy's said in a BSE filing.

Dr Reddy's Laboratories launches anti-smoking drug in USA market

According to a release by the city-based drug maker, the generic Zyban has been approved by the U.S. Food and Drug Administration.

Dr Reddy's Laboratories launches Roche's Avastin biosimilar in India

The company's biosimilar, Versavo, is available in strengths of 100 mg and 400 mg single use vials, Dr Reddy's said in a statement.

Dr Reddy's falls nearly 2% after co clarifies on NuvaRing-USFDA issue; Citi cuts target by 6.5%

The USFDA sends the applicant a CRL if the agency determines that it will not approve the application, or ANDA, in its present form for one or more reason

Dr Reddy's dips 8% after receiving Complete Response Letter from USFDA; Citi cuts target

Global brokerage Citi slashed price target to Rs 2,375 from Rs 2,540 per share, citing likely more delay in female contraceptive drug launch after fresh Complete Response Letter from US FDA.

USFDA completes audit of Dr Reddy's Louisiana-based facility

The audit of our formulations manufacturing facility at Shreveport, Louisiana, USA by the the US Food and Drug Administration (USFDA), has been completed on August 8, 2019.

Accumulate Dr. Reddy's Laboratories; target of Rs 2997: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 2997 in its research report dated July 29, 2019.

Dr Reddy's Laboratories launches generic pregabalin capsules in US

The product is a generic version of C P Pharmaceuticals International C V's Lyrica capsules which had US sales of around $5,462 million for the twelve months ended May 2019.

Brokerages see up to 26% upside in Dr Reddy’s post Q1 results; here's why?

CLSA maintained its buy rating on Dr Reddy’s and also stressed on the fact that the company is on track to deliver on its realigned strategy.

Dr Reddys Labs Standalone June 2019 Net Sales at Rs 2,508.70 crore, down 4.16% Y-o-Y

Dr Reddy's Laboratories launches insomnia treatment tablets in US

The tablets are indicated for the treatment of insomnia characterised by difficulty with sleep onset.

Dr Reddy's completes sale of US rights for 2 neurology products

Earlier in June 2019 Dr Reddy's had said in a regulatory filing that it had entered into a definitive asset purchase agreement with Upsher-Smith Laboratories LLC to sell its US and select territory rights for the two products to the latter.

Dr. Reddy’s Laboratories Q1 PAT seen up 13.6% YoY to Rs. 540.8 cr: Prabhudas Lilladher

Net Sales are expected to increase by 2.2 percent Y-o-Y (down 5.2 percent Q-o-Q) to Rs. 3,820.3 crore, according to Prabhudas Lilladher.

Dr Reddy's Labs launches generic injection indicated for abortion in US

Shares of Dr Reddy's Labs were trading at Rs 2,590 per scrip on BSE, down 1.46% from the previous close.

Dr Reddy's Labs rallies 3% on Greek drug regulator nod to Srikakulam unit

Dr Reddy's Srikakulam unit has received a clearance letter from Greek drug regulator, reported CNBC-TV18

Dr Reddys Labs slips 2% on agreement to sell neurology branded products

Dr Reddy's Labs will commercialise these products through its wholly owned subsidiary, Promius Pharma, LLC.

Dr Reddys Laboratories to spend upto $300 million on R&D in FY20

The company would continue to focus on R&D for some interesting pipeline of proprietary products.

Dr Reddys Labs Standalone March 2019 Net Sales at Rs 2,645.20 crore, up 6.13% Y-o-Y

Dr Reddys Labs Consolidated March 2019 Net Sales at Rs 4,029.60 crore, up 13.39% Y-o-Y

Dr Reddy's Q4 preview: Profit to rise 37% YoY to Rs 413cr; EBITDA margin may touch 23%

Narnolia Financial Advisors expects the pharma company to report a net profit of Rs 545 crore as against Rs 500 crore in the last quarter

Dr Reddy's launches skin treatment drug in US

The company has launched its product, which is generic version of Merck Sharp & Dohme Corp's Cubicin, after obtaining approval from the US Food and Drug Administration (USFDA), the Hyderabad-based firm said in a statement.

Dr Reddy's Laboratories launches generic testosterone gel in US market

The company's testosterone gel 1.62 percent is a therapeutic equivalent generic version of AndroGel 1.62 percent of AbbVie Inc.

Dr Reddy's Laboratories, Cipla arm recall drugs in US market

Dr Reddy's Laboratories Inc, a subsidiary of the Hyderabad-based Dr Reddy's Laboratories, is voluntarily recalling the affected lot of bottles on account of certain deviations from the Current Good Manufacturing Practice (CGMP) regulations.